Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948436 | 1.00 | MEN1 (0.53) | MEN1KMT2ACYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2948433 | 1.00 | MEN1 (0.53) | MEN1KMT2ACYP2D6CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL9063195 | 0.99 | MEN1 (0.52) | MEN1KMT2ACYP2D6CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL9063197 | 0.99 | MEN1 (0.52) | MEN1KMT2ACYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9190379 | 0.95 | GAA (0.49) | MEN1KMT2ACYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9195269 | 0.95 | GAA (0.49) | MEN1KMT2ACYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9190376 | 0.95 | GAA (0.49) | MEN1KMT2ACYP2D6CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL9063527 | 0.93 | GAA (0.48) | MEN1KMT2ACYP2D6CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL9063530 | 0.93 | GAA (0.48) | MEN1KMT2ACYP2D6CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL9063529 | 0.93 | GAA (0.48) | MEN1KMT2ACYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0463560-B1 | New antiepileptic agents | CIBA GEIGY AG (CH) | 1995-10-25 | — | — | EP | claimed |
| EP-0463560-A1 | New antiepileptic agents | CIBA-GEIGY AG (CH) | 1992-01-02 | — | — | EP | claimed |
| US-7749985-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090286759-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-7585996-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-20080146526-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. | 2008-06-19 | — | — | US | disclosed |
| WO-2008033572-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-5545631-A | GAMMA-AMINOBUTYRIC ACID ANTAGONIST; TREATS PETIT-MAL TYPE EPILEPSIES | CIBA-GEIGY CORPORATION (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0463560-B1 | New antiepileptic agents | CIBA GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
| US-5407922-A | GABA antagonists | CIBA-GEIGY CORPORATION (US) | 1995-04-18 | — | — | US | disclosed |
| US-5229379-A | Gamma-aminobutyric acid antagonists | CIBA-GEIGY CORPORATION (US) | 1993-07-20 | — | — | US | disclosed |
| EP-0463560-A1 | New antiepileptic agents | CIBA-GEIGY AG (CH) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286759-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, NAPEPLD, AASDHPPT | MEN1 2553/4885KMT2A 999/4885CYP2D6 306/4885 |
| US-20080146526-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | APEH, NAPEPLD, AASDHPPT | MEN1 2553/4885KMT2A 999/4885CYP2D6 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.